美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

GSK plc ADRhedged

69.68

-1.5993-2.24%

盤後：69.680.00000.00%16:10 EDT

成交量：233

成交額：1.63萬

市值：69.69萬

市盈率：- -

高：70.00

開：69.85

低：69.68

收：71.28

52周最高：85.03

52周最低：55.03

股本：1.00萬

流通股本：1.00萬

量比：0.51

換手率：2.33%

股息：2.08

股息率：2.99%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

葛蘭素史克首席執行官：媒體電話會議發言稱，我們認為公司現有營收與收益流規模充足，足以抵消艾滋病藥物專利失效帶來的損失。

葛蘭素史克首席執行官就劍橋投資表示，我們並未尋求英國政府支持。

葛蘭素史克擬在英國劍橋生物醫學園區建立新旗艦研發中心

葛蘭素史克美股盤前升逾5%

葛蘭素史克：未來三年內向英國投資4億英鎊

葛蘭素史克在倫敦上漲2.5%

每日经济新闻

葛蘭素史克股價上漲2.5%，觸及盤中高點，此前該公司公布的盈利報告超出預期。

葛蘭素史克表示其目標是到2029年全面實現每年19億英鎊的成本節約。

葛蘭素史克Q2調整後EPS為50.5便士超預期

盤前異動 | 存儲、半導體板塊集體下挫，西部數據、美光跌超5%，海力士跌超4%、英特爾、AMD跌超4%

老虎资讯综合

GSK憑藉Jideytro獲得美國食品藥品監督管理局（FDA）的早期批准，正式進軍肺癌藥物市場

創新藥研發加速遇「猴荒」

葛蘭素史克(GSK)股票7月20日收盤下跌3.17%：釋放什麼信號？

TradingKey中文

葛蘭素史克(GSK)股票7月17日盤中下跌3.06%：原因全解讀

TradingKey中文

葛蘭素史克(GSK)跌2.3% 止咳新藥三期臨床失利 20億併購核心管線宣告終止開發

第3次更新-葛蘭素史克因晚期臨床試驗未達預期，停止開發慢性咳嗽藥物

英硅智能早盤升逾7% 與康哲藥業達成AI+創新藥研發新合作

前沿生物收入調減揭示渠道壓力，經營虧損持續擴大

中國生物製藥早盤升逾5% 與GSK進一步深化獨家戰略合作

GSK將兩款呼吸疾病藥物中國商業化權益授予正大天晴，MNC在華戰略調整加速

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/GSKH/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":69.6792,"timestamp":1787860800000,"preClose":71.2785,"halted":0,"volume":233,"hourTrading":{"tag":"盘后","latestPrice":69.6792,"preClose":69.6792,"latestTime":"16:10 EDT","volume":6,"amount":418.0752,"timestamp":1787861404893,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.022437340853132426,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"盤後交易","change":-1.5993,"latestTime":"08-27 17:41:28 EDT","open":69.85,"high":70,"low":69.6792,"amount":16290,"amplitude":0.004501,"askPrice":104.47,"askSize":200,"bidPrice":34.83,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787875200000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":71.2785,"nav":71.844869,"aum":718520.534869,"dividendRate":0.02987,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":69.6792,"preClose":69.6792,"latestTime":"16:10 EDT","volume":6,"amount":418.0752,"timestamp":1787861404893,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.506742,"impliedVol":0.164,"impliedVolPercentile":0.3204},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.506742,"shares":10001,"dividePrice":2.0813,"high":70,"amplitude":0.004501,"preClose":71.2785,"low":69.6792,"week52Low":55.03,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":69.6792,"eps":0,"divideRate":0.02987,"volume":233,"delay":0,"ttmEps":0,"open":69.85,"prevYearClose":68.2031,"prevWeekClose":72.35,"prevMonthClose":71.6488,"prevQuarterClose":73.8574,"fiveDayClose":71.6836,"twentyDayClose":72.0255,"sixtyDayClose":69.1121},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654001756","title":"葛蘭素史克首席執行官：媒體電話會議發言稱，我們認為公司現有營收與收益流規模充足，足以抵消艾滋病藥物專利失效帶來的損失。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001756","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001756?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 20:03","pubTimestamp":1785240196,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GSK","BK4532","GSKH","LU1829250122.USD","BK4585","BK4007","GSK.UK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654016400","title":"葛蘭素史克首席執行官就劍橋投資表示，我們並未尋求英國政府支持。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654016400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654016400?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:52","pubTimestamp":1785239557,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GSK.UK","GSKH","GSK","BK4588","BK4007","LU1829250122.USD","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009999","title":"葛蘭素史克擬在英國劍橋生物醫學園區建立新旗艦研發中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009999","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009999?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:26","pubTimestamp":1785238009,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1829250122.USD","BK4585","BK4532","BK4588","GSK.UK","GSK","BK4007","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654695009","title":"葛蘭素史克美股盤前升逾5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654695009","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654695009?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:23","pubTimestamp":1785237809,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1829250122.USD","GSK.UK","BK4588","BK4007","BK4585","GSK","GSKH","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654300952","title":"葛蘭素史克：未來三年內向英國投資4億英鎊","url":"https://stock-news.laohu8.com/highlight/detail?id=2654300952","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654300952?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:21","pubTimestamp":1785237674,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["GSK.UK","BK4007","LU1829250122.USD","GSKH","BK4585","BK4588","BK4532","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654853009","title":"葛蘭素史克在倫敦上漲2.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654853009","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654853009?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:12","pubTimestamp":1785237141,"startTime":"0","endTime":"0","summary":"葛兰素史克在伦敦上涨2.5%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823635566.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823635566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","LU1829250122.USD","GSK","BK4532","GSKH","BK4585","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654800605","title":"葛蘭素史克股價上漲2.5%，觸及盤中高點，此前該公司公布的盈利報告超出預期。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654800605","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654800605?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:09","pubTimestamp":1785236998,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","GSK.UK","GSK","LU1829250122.USD","BK4588","BK4585","GSKH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654900642","title":"葛蘭素史克表示其目標是到2029年全面實現每年19億英鎊的成本節約。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654900642","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654900642?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:04","pubTimestamp":1785236671,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","GSK.UK","BK4007","GSK","GSKH","LU1829250122.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006157","title":"葛蘭素史克Q2調整後EPS為50.5便士 超預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006157","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006157?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:03","pubTimestamp":1785236596,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["GSK.UK","BK4585","BK4532","BK4007","BK4588","LU1829250122.USD","GSK","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174181337","title":"盤前異動 | 存儲、半導體板塊集體下挫，西部數據、美光跌超5%，海力士跌超4%、英特爾、AMD跌超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174181337","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174181337?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 16:03","pubTimestamp":1785225827,"startTime":"0","endTime":"0","summary":"7月28日，美股盘前三大股指期货涨跌不一，道指期货升0.14%，标普500指数期货跌0.18%，纳指期货跌0.89%。存储概念股集体下挫，西部数据、闪迪、美光跌超5%，希捷科技跌超4%，SK海力士跌近4%；光通信概念股普跌，康宁跌超3%，CRDO跌超2%；半导体板块集体下跌，英特尔、AMD跌超4%，阿斯麦跌超3%；热门中概股盘前涨跌不一，网易涨近2%，金山云跌近2%，腾讯音乐跌超1%，小鹏集团跌近1%；","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLW","PYPG","SNDG","AMDY","CRDU","PYPY","BOEG","GSKH","KO","KC","MUD","ASMG","MUZ","PYPL","SNDC","SNDQ","WDCX","AMDD","BA","XPEV","INTC","SK","AMUU","BOEU","MIC","SNXX","BOED","AMDW","SNDU","INTW","SKUU","07709","SKHX","MULL","MUYY","MU","WDC","SKHZ","ASMU","GSK","SKHU","AMDG","LINT","STX","AMDU","MUU","SKHY","XPEG","GLWG","HYNX","SKDD","AMDL","TME","CRDO","NTES","SNDK","DAMD","AMYY","ASML","AMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653767521","title":"GSK憑藉Jideytro獲得美國食品藥品監督管理局（FDA）的早期批准，正式進軍肺癌藥物市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2653767521","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653767521?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 02:12","pubTimestamp":1784743973,"startTime":"0","endTime":"0","summary":"更新 2-GSK凭借Jideytro获得美国食品药品监督管理局的早期批准，正式进军肺癌药物市场重写第1至4段，补充有关药品审批及近期交易的细节Padmanabhan Ananthan/Bhanvi Satija路透7月22日-葛兰素史克GSK.L周三表示，美国食品药品监督管理局已批准其用于治疗某种肺癌的药物。此次批准标志着GSK正式进军利润丰厚的肺癌治疗市场，且批准时间早于FDA设定的9月18日目标行动日期。预计美国食品药品监督管理局将于11月前就Nuvalent的第二款肺癌药物neladalkib作出审批决定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nL4T43O1YH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","GSK.UK","GSK","BK4532","BK4585","BK4588","GSKH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"創新藥研發加速遇「猴荒」","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653584157?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BIOY","GSKH","PBE","LFSC","XLVI","APXH","BK4585","GDOC","SBIO","WRND","BK4588","BBP","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653245757","title":"葛蘭素史克(GSK)股票7月20日收盤下跌3.17%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2653245757","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653245757?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 04:16","pubTimestamp":1784578570,"startTime":"0","endTime":"0","summary":"• 受到持续的Zantac诉讼债务以及监管不确定性的影响，GSK股价面临下行压力。\n• 疫苗市场竞争加剧和研发成本上升影响了投资者情绪。\n• 包括威廉指标（Williams %R）在内的技术指标显示该股可能面临潜在的抛售压力。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262042327-market-movers-gsk-20260720","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","GSKH","BK4585","LU1829250122.USD","BK4007","GSK","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652287844","title":"葛蘭素史克(GSK)股票7月17日盤中下跌3.06%：原因全解讀","url":"https://stock-news.laohu8.com/highlight/detail?id=2652287844","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652287844?lang=zh_tw&edition=fundamental","pubTime":"2026-07-18 02:16","pubTimestamp":1784312169,"startTime":"0","endTime":"0","summary":"• 由于持续进行的善胃得（Zantac）诉讼及潜在的和解负债，葛兰素史克（GSK）股价面临波动。\n• 行业定价压力和机构投资转向导致股价表现走低。\n• 临床管线研究结果的不确定性以及汇率波动影响了该公司的估值和收益。","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262038450-market-movers-gsk-20260717","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSKH","LU1829250122.USD","GSK.UK","BK4532","BK4007","BK4588","BK4585","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652784289","title":"葛蘭素史克(GSK)跌2.3% 止咳新藥三期臨床失利 20億併購核心管線宣告終止開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2652784289","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652784289?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 22:32","pubTimestamp":1784298747,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英国药企葛兰素史克 股价承压，报51.56美元，跌2.29%。该药物为高选择性 P2X3 受体拮抗剂，是 2023 年 GSK 斥 20 亿美元全额现金收购 Bellus Health 的核心资产，原本被市场寄予厚望，用于填补难治性慢性咳嗽临床空白。本次 20 亿并购的核心呼吸管线宣告失败，大幅削弱公司呼吸板块中长期增长预期，市场担忧并购投入回报不及预期；肠易激综合征赛道市场空间相对有限，难以完全对冲止咳适应症临床失利带来的估值压力。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302703","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","GSKH","XMMO","KCE","GSK","LU1829250122.USD","BK4007","CALF","GSK.UK","BK4585","MYLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652883682","title":"第3次更新-葛蘭素史克因晚期臨床試驗未達預期，停止開發慢性咳嗽藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2652883682","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652883682?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 19:56","pubTimestamp":1784289375,"startTime":"0","endTime":"0","summary":"但也有人认为此次临床试验失败尚在可控范围内。两种剂量均未达到关键次要目标，包括来自“慢性咳嗽日记”的患者报告结果。该公司还计划分享相关数据，以促进对难治性慢性咳嗽这一目前治疗选择有限的疾病的科学理解。全球每年约有1000万患者罹患此病，该病症可能导致患者每天咳嗽超过900次。葛兰素史克于2023年以20亿美元收购Bellus Health公司，从而获得了该药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nL4T43J0WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","BK4585","BK4532","BK4007","GSK","BK4588","GSKH","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盤升逾7% 與康哲藥業達成AI+創新藥研發新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651162210?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":"　　英硅智能早盘涨超7%，截至发稿，股价上涨6.21%，报45.48港元，成交额3.32亿港元。　　7月13日，据英硅智能官微消息，公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。　　根据合作协议，双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，双方共同推进该研发项目的合作开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BMCWC346.EUR","IBB","BK4588","LFSC","AIPO","VTHR","LU2488822045.USD","GDOC","PBE","BK1191","SBIO","00867","SG9999015978.USD","AGIX","SG9999015945.SGD","SG9999004220.SGD","WRND","BK4585","IE00BVYPNP33.GBP","IE00BVYPNQ40.USD","IE00BGHQDM52.EUR","SG9999015986.USD","BK1593","CHAT","BBP","IE00BYV24P56.USD","QTOC","ARTY","SG9999015952.SGD","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650902698","title":"前沿生物收入調減揭示渠道壓力，經營虧損持續擴大","url":"https://stock-news.laohu8.com/highlight/detail?id=2650902698","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650902698?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 14:18","pubTimestamp":1783664280,"startTime":"0","endTime":"0","summary":"前沿生物近日就上交所2025年年报问询函作出回复，对收入确认调整、经销商库存、研发投入及现金流等问题逐一说明。回复内容揭示了公司在核心产品增长、渠道健康度和费用控制等方面面临的现实压力。艾可宁终端销售能否回暖、渠道库存能否有效消化、费用支出能否得到控制，仍是决定公司未来经营走向的关键变量。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-07-10/doc-inihhzry7114679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4532","BK4588","GSK","LU1829250122.USD","GSKH","BK4585","GSK.UK","SPHQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650910625","title":"中國生物製藥早盤升逾5% 與GSK進一步深化獨家戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2650910625","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650910625?lang=zh_tw&edition=fundamental","pubTime":"2026-07-09 10:12","pubTimestamp":1783563120,"startTime":"0","endTime":"0","summary":"　　中国生物制药早盘涨超5%，截至发稿，股价上涨5.39%，现报5.08港元，成交额2.39亿港元。　　7月8日，中国生物制药发布公告，集团附属公司正大天晴药业集团股份有限公司进一步深化与葛兰素史克“GSK”于2026年5月达成的独家战略合作，推动两款呼吸领域重磅创新药物惠及更多中国患者。本次合作是集团与GSK战略合作的又一重要进展，标志着双方合作领域从肝病进一步拓展至呼吸系统疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-09/doc-inihench4479325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01177","BK1515","HK0000165453.HKD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK4532","GSK.UK","BK4007","GSK","IE00BZ08YT58.USD","BK1521","GSKH","LU1829250122.USD","BK4585","BK1191","BK4588","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649096193","title":"GSK將兩款呼吸疾病藥物中國商業化權益授予正大天晴，MNC在華戰略調整加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2649096193","media":"蓝鲸财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649096193?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 16:50","pubTimestamp":1783500612,"startTime":"0","endTime":"0","summary":"而此前，就在今年5月，正大天晴获得GSK乙肝新药Bepirovirsen在中国内地的独家商业化权利。事实上，不只GSK，跨国药企在华战略近年来正在加速调整。一方面，MNC将成熟管线的商业化权益交给国内企业，另一方面，MNC正在加大力度购买中国药企的创新管线。从商业化到研发，内、外资药企的战略调整还在加速。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783500577933587278","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["GSK.UK","GSKH","GSK","BK4588","BK4007","LU1829250122.USD","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":91,"code":"91000000","status":"200"}]}}